Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | Būtiski notikumi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2009-11-12 09:56:22 |
Versijas komentārs | |
Teksts |
Joint Stock Company “Grindeks” informs on launching of Rimantadine-Grindeks 50mg – the effective and recognized antiviral medication for treatment of seasonal flu. After the receiving of registration approval from the State Agency of Medicines, “Grindeks” will start to manufacture this medicine and promises that Rimantadine-Grindeks 50mg will be available at the local pharmacies in nearest months. The active substance of Rimantadine-Grindeks is rimantadine hydrochloride and its commonly used chemical name is rimantadine. For the first time the substance was synthesized in Latvian Institute of Organic Synthesis 40 years ago. Chairman of the Board of “Grindeks” Jānis Romanovskis: “In response to expansion of pandemic influenza in Latvia, we will offer Rimantadine-Grindeks – effective and recognized antiviral medication for treatment of seasonal flu. According to the data of World Health Organization (WHO), so called “swine flu” will be acute until the New Year and will prevail over the seasonal flu, which in turn will be acute after the New Year. I am pleased that Rimantadine-Grindeks will help Latvian society to fight against the flu and to recover!” “Grindeks” plans to register and manufacture Rimantadine-Grindeks 100mg. According to the WHO Guidelines for Pharmacological Management
of Pandemic 2009 Influenza and other Influenza Viruses, published
on 20 August 2009, rimantadine has been acknowledged as efficient
antiviral medication. About “Grindeks”
Further information: Laila Kļaviņa
|
Pielikumi |
|